



Celsion Corporation
Investor Relations Department
997 Lenox Drive
Suite 100
Lawrenceville, NJ 08648
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: CLSN

Last Trade:	3.83
Trade Time:	4:00 PM ET Oct 17, 2017
Change:	-0.25 ▼ (-6.127%)
Day Range	3.54 - 4.04
52-Week Range	1.24 - 16.39
Volume	2,747,157

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Celsion Corporation is an oncology drug development company focused on the development of efficient, effective, and targeted therapies for the treatment of cancer. Founded in 1985, the company has developed elegant therapeutic approaches that deliver high concentrations of widely used anti-cancer agents directly to the tumor site, maximizing efficacy while minimizing the side-effects of systemic treatments, with the goal of improving patient outcomes in underserved cancer indications. The foundation for this research is a heat-sensitive liposomal nanoparticle licensed from Duke Universit... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Oct 17, 2017*
[Celsion Provides Summary of Research and Development Day Held on Thursday, October 12, 2017](#)
- Oct 16, 2017*
[Celsion Announces Publication of the HEAT Study Manuscript in the High Impact Journal, Clinical Cancer Research](#)
- Oct 12, 2017*
[Celsion to Host Research and Development \(R&D\) Day on Thursday, October 12, 2017](#)
- Oct 4, 2017*
[Celsion Corporation Announces Gross Proceeds of \\$15.6 Million from the Exercise of Existing Common Stock Warrants](#)
- Oct 4, 2017*
[Celsion to Host Research and Development Update October 12, 2017](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 24, 2017*
[Annual Report \(10-K\)](#)
- Apr 4, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 14, 2017*
[Quarterly Report \(10-Q\)](#)
- May 12, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 10, 2016*
[Quarterly Report \(10-Q\)](#)